Genome BC, based in Vancouver, has invested Canadian $1.2 million into Stoko Design Inc., a Vancouver-based startup developing next-gen knee-brace technology.
Stoko’s first-to-market product, the K1, is a compression tight with integrated joint support that mimics the body’s natural structures with the support of a traditional knee brace.
“We believe that traditional bracing is obsolete, as many medical practitioners are already moving towards active rehabilitation methods,” said Zack Eberwein, CEO, Stoko. “The K1 is uniquely positioned for this type of treatment, offering athletes and practitioners the ability to adjust support for any level of instability or activity as they return to sport after an injury. Local investors, such as Genome BC, have been and will continue to be critical in enabling companies like ours to commercialize game-changing technologies and expand market share.”
Unlike its traditional competitors, Stoko offers a direct-to-consumer and business-to-business model. The K1 is eligible for medical coverage by some healthcare providers.
“Genome BC invests in cutting-edge, innovative life sciences companies,” said Dr. Tony Brooks, CFO and vice president, entrepreneurship & commercialization, Genome BC. “Stoko has demonstrated there is a market and an unmet need for this type of product. Our investment will be directed towards manufacturing and marketing efforts to help grow the company.”
